Given the protective benefits of TLR9-induced Type I IFN in experimental colitis and reported success of recombinant IFN-β therapy in human colitis, we have developed a transgenic Lactobacillus strain that constitutively expresses murine IFN-β. Here, TLR9 is linked to colitis.